+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Drugs Market, by Drug Class, by Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • PDF Icon

    Report

  • 304 Pages
  • July 2022
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5641009
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics


The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.

Key features of the study:

  • This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 - 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global pulmonary drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Detailed Segmentation:


Global Pulmonary Drugs Market, By Drug Class:

  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others

Global Pulmonary Drugs Market, By Application:

  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others

Global Pulmonary Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Global Pulmonary Drugs Market, By Geography:

  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa

Company Profiles:

  • Sanofi SA
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Meda Pharmaceuticals
  • Circassia Pharmaceuticals Plc.
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Mallinckrodt Pharmaceuticals Plc.
  • Cheisi Farmaceutici S.p.A
  • Zambon Company S.p.A
  • Alaxia SAS
  • Merck Sharp & Dohme Limited
Frequently Asked Questions about the Global Pulmonary Drugs Market

What is the estimated value of the Global Pulmonary Drugs Market?

The Global Pulmonary Drugs Market was estimated to be valued at $41.32 Billion in 2022.

What is the growth rate of the Global Pulmonary Drugs Market?

The growth rate of the Global Pulmonary Drugs Market is 8.1%, with an estimated value of $77.31 Billion by 2030.

What is the forecasted size of the Global Pulmonary Drugs Market?

The Global Pulmonary Drugs Market is estimated to be worth $77.31 Billion by 2030.

Who are the key companies in the Global Pulmonary Drugs Market?

Key companies in the Global Pulmonary Drugs Market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceutici S.p.A, Zambon Company S.p.A and Merck Sharp & Dohme Limited.

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations
2. Market Purview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Application
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
  • Publisher Opportunity Map
3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Regulatory Scenario
  • Pipeline Analysis
  • Promotional Activities and Campaigns
  • Supply Chain Analysis
  • PEST Analysis
  • Epidemiology
4. Global Pulmonary Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market
5. Global Pulmonary Drugs Market, By Drug Class, 2017 - 2030, (US$ Billion)
  • Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Inhaled Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Long Acting Beta-2 Agonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Antihistamines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Vasodilators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Short Acting Beta-2 Agonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
6. Global Pulmonary Drugs Market, By Application , 2017 - 2030, (US$ Billion)
  • Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Asthma & COPD
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Allergic Rhinitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Pulmonary Arterial Hypertension
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Cystic Fibrosis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
7. Global Pulmonary Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
  • Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • E-Commerce
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
8. Global Pulmonary Drugs Market, By Region, 2017 - 2030, (US$ Billion)
  • Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
  • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • UK
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa
9. Competitive Landscape
  • Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
  • Sanofi SA*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Meda Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Circassia Pharmaceuticals Plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • AstraZeneca Plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • GlaxoSmithKline Plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Mallinckrodt Pharmaceuticals Plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Cheisi Farmaceutici S.p.A
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Zambon Company S.p.A
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Alaxia SAS
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Merck Sharp & Dohme Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Analyst Views
10. Section
  • References
  • Research Methodology
  • About Us and Sales Contact

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Sanofi SA
  • Meda Pharmaceuticals
  • Circassia Pharmaceuticals Plc.
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Mallinckrodt Pharmaceuticals Plc.
  • Cheisi Farmaceutici S.p.A
  • Zambon Company S.p.A
  • Alaxia SAS
  • Merck Sharp & Dohme Limited